Not to be administered IV, intraarterially (apart from selective catheterisation) or intrathecally. History of hypersensitivity. Patients w/ impaired resp function, cardioresp failure or right ventricular overload, especially the elderly. Uncontrolled asthma. Latent hyperthyroidism or thyroid autonomy. Perform thyroid function test consequently prior to radiological exam. Decompensated liver cirrhosis (Child-Pugh ≥8), advanced liver dysfunction, macroscopic invasion &/or extra-hepatic spread of the tumour. Carefully monitor oesophageal varices. Perform endoscope sclerotherapy/ligature prior TACE procedure if risk of rupture is demonstrated. Maintain medical monitoring & an indwelling IV catheter during exam. Dehydrated patients, renal failure, diabetes, severe heart failure, monoclonal gammopathy (multiple myeloma, Waldenstrom's macroglobulinemia), history of renal failure after administration of iodinated contrast agents. Hydrate patients prior to & after exam. Concomitant use w/ nephrotoxic drugs eg, aminoglycosides, organoplatinums, high doses of MTX, pentamidine, foscarnet & certain antiviral agents (aciclovir, ganciclovir, valaciclovir, adefovir, cidoforvir, tenofovir), vancomycin, amphotericin B, immunosuppressors eg, cyclosporine or tacrolimus, ifosfamide. Allow at least 48 hr between radiological exam or interventions w/ iodinated contrast agents inj or delay further exam or interventions until renal function returns to baseline. Monitor serum creatinine in diabetics w/ metformin for lactic acidosis. Discontinue metformin before & for at least 48 hr after contrast agent administration or renal function returns to baseline. Assess CV &/or pulmonary co-morbidities prior to initiation of TACE procedure. Avoid any vascular penetration & do not inj into bleeding or trauma areas. Childn <1 yr. Elderly (atheromatous). Lactation (discontinue).